Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZA8M7)

Drug Name

2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid Drug Info

Synonyms

4-anilinopyrimidine 7a; CHEMBL394869; BDBM15986; AKOS029246132; 2-{[2-(butylamino)pyrimidin-4-yl]amino}benzoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Stress-activated protein kinase JNK1 (JNK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NKP-1339	DM5AWK1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[3]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[3]
7-azaindole derivative 1	DMQL5B7	N. A.	N. A.	Patented	[3]
7-azaindole derivative 5	DMV3H98	N. A.	N. A.	Patented	[3]
PMID25991433-Compound-P6	DMNDVC9	N. A.	N. A.	Patented	[3]
PMID25991433-Compound-J3	DM17P3F	N. A.	N. A.	Patented	[3]
PMID25991433-Compound-P1	DMD8AX6	N. A.	N. A.	Patented	[3]
PMID25991433-Compound-O3	DMVOWS5	N. A.	N. A.	Patented	[3]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Stress-activated protein kinase JNK1 (JNK1)	TT0K6EO	MK08_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
3	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.